Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.33 |
| ▸ | TUBB | P07437 | 1/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.33 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004135 | 0.86 | ALDH1A1 (0.46) | SMN1; SMN2HTTALDH1A1HPGDLMNA | |
| SCHEMBL2261587 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2HTTALDH1A1HPGDLMNA | |
| SCHEMBL200586 | 0.78 | CA5A (0.43) | HPGDLMNAL3MBTL1NOTUMMAPT | |
| SCHEMBL12476103 | 0.77 | PARP1 (0.46) | SMN1; SMN2HTTALDH1A1HPGDLMNA | |
| SCHEMBL7895707 | 0.77 | CES2 (0.40) | SMN1; SMN2ALDH1A1HPGDLMNAERN1 | |
| SCHEMBL200827 | 0.75 | TPMT (0.48) | SMN1; SMN2ALDH1A1HPGDLMNAMAPT | |
| SCHEMBL29528960 | 0.75 | TPMT (0.48) | SMN1; SMN2ALDH1A1HPGDLMNAMAPT | |
| SCHEMBL3488840 | 0.74 | CA12 (0.46) | SMN1; SMN2HTTALDH1A1HPGDLMNA | |
| SCHEMBL16396395 | 0.74 | NOTUM (0.54) | SMN1; SMN2HTTALDH1A1HPGDLMNA | |
| SCHEMBL16396506 | 0.74 | SMN1; SMN2 (0.38) | SMN1; SMN2HTTALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989454-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989454-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989454-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2234995-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-10-08 | — | — | US | disclosed |
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-10-08 | — | — | US | disclosed |
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-10-08 | — | — | US | disclosed |
| WO-2009077385-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | SMN1; SMN2 4394/4885HTT 4578/4885ALDH1A1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.